TELA Bio, Inc. (TELA)

Market Cap	51.21M
Revenue (ttm)	77.06M
Net Income (ttm)	-39.00M
Shares Out	43.77M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,148
Open	1.090
Previous Close	1.060
Day's Range	1.050 - 1.180
52-Week Range	0.865 - 3.200
Beta	0.87
Analysts	Buy
Price Target	3.42 (+192.31%)
Earnings Date	Nov 13, 2025

About TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 8, 2019
• Employees: 209
• Stock Exchange: NASDAQ
• Ticker Symbol: TELA
• Website: https://www.telabio.com

Financial Performance

In 2024, TELA Bio's revenue was $69.30 million, an increase of 18.56% compared to the previous year's $58.45 million. Losses were -$37.84 million, -18.91% less than in 2023.

Analyst Summary

According to 3 analysts, the average rating for TELA stock is "Buy." The 12-month stock price target is $3.42, which is an increase of 192.31% from the latest price.

Price Target

$3.42

(192.31% upside)

Analyst Consensus: Buy